Medicare Enrolled
Dr. Eric Harris, D.O.
Hematology · Daytona Beach, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Harris from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Harris?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Harris
Dr. Eric Harris is a hematology specialist in Daytona Beach, FL, with 17 years of NPI registration. Based on federal Medicare data, Dr. Harris performed 87,698 Medicare services across 2,247 unique beneficiaries.
Between the years covered by Open Payments, Dr. Harris received a total of $150,121 from 85 pharmaceutical and/or device companies across 879 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Harris is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 49% volume in FL
$150,121 industry payments
Florida License Status
FL DOH · MQA1
Active license
None
Board action on record
0
Recent admin complaints
| Profession | License # | Status | Expires | Board Action |
|---|---|---|---|---|
| Osteopathic Physician | 12441 | Clear | March 31, 2028 | — |
Data from Florida Department of Health Medical Quality Assurance.
License records are public under Chapter 119, Florida Statutes.
Verify directly on FL DOH →
Medicare Practice Summary
Medicare Utilization ↗87,698
Medicare services
Top 49% in FL for hematology
2,247
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,159 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 27,400 | $43 | $137 |
| Iron infusion (Injectafer) | 20,250 | $1 | $3 |
| Iron infusion (Feraheme) | 14,790 | $0 | $4 |
| Anti-nausea injection (aprepitant) | 10,400 | $1 | $5 |
| Denosumab injection (Prolia/Xgeva) | 3,900 | $19 | $51 |
| Dexamethasone injection (steroid) | 2,044 | $0 | $3 |
| Complete blood count (CBC) with differential | 1,322 | $8 | $29 |
| Blood draw (venipuncture) | 1,102 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,030 | $1 | $28 |
| Anti-nausea injection (ondansetron/Zofran) | 800 | $0 | $9 |
| Office visit, established patient (20-29 min) | 614 | $64 | $239 |
| Injection of additional new drug or substance into vein | 547 | $12 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 524 | $96 | $378 |
| Injection, carboplatin, 50 mg | 451 | $2 | $41 |
| Office visit, established patient (30-39 min) | 434 | $95 | $339 |
| Drug injection, under skin or into muscle | 359 | $10 | $69 |
| Injection, diphenhydramine hcl, up to 50 mg | 170 | $1 | $3 |
| Administration of additional new drug or substance into vein, 1 hour or less | 137 | $48 | $178 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 116 | $47 | $189 |
| Injection, zoledronic acid, 1 mg | 116 | $7 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 114 | $22 | $84 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 104 | $1 | $6 |
| Hospital follow-up visit, moderate complexity | 102 | $62 | $197 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 97 | $3 | $11 |
| Initial hospital admission, high complexity | 84 | $136 | $556 |
| Injection of drug or substance into vein | 75 | $28 | $156 |
| Administration of chemotherapy into vein, each additional hour | 70 | $22 | $79 |
| Automated urinalysis | 65 | $2 | $8 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 59 | $24 | $89 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 57 | $134 | $562 |
| Infusion into a vein for hydration, each additional hour | 45 | $10 | $42 |
| New patient office visit, complex (60-74 min) | 43 | $167 | $585 |
| Administration of additional new drug or substance into vein using push technique | 41 | $42 | $170 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 40 | $16 | $59 |
| Infusion into a vein for hydration, 31-60 minutes | 38 | $25 | $156 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 37 | $15 | $56 |
| Infusion, normal saline solution , 1000 cc | 37 | $2 | $7 |
| Hospital follow-up visit, high complexity | 20 | $94 | $285 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 19 | $1 | $7 |
| New patient office visit (45-59 min) | 17 | $115 | $453 |
| Office visit, established patient (10-19 min) | 16 | $41 | $147 |
| Office visit, established patient, complex (40-54 min) | 12 | $140 | $474 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
40.4% high complexity
54.9% medium
4.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$150,121
Total received (2018-2024)
Avg $21,446/year across 7 years
Top 3% in FL for hematology
85
Companies
879
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$126,110 (84.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$12,432 (8.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,364 (6.9%)
Other
Charitable contributions, space rental, and other categories
$1,215 (0.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,664
2023
$2,886
2022
$8,656
2021
$22,820
2020
$13,712
2019
$42,932
2018
$56,451
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$71,799
E.R. Squibb & Sons, L.L.C.
$41,726
Gilead Sciences, Inc.
$13,619
AstraZeneca Pharmaceuticals LP
$8,488
Immunomedics, Inc.
$2,500
Celgene Corporation
$1,333
Rigel Pharmaceuticals, Inc.
$1,025
Seattle Genetics, Inc.
$949
PFIZER INC.
$650
Janssen Biotech, Inc.
$551
Genentech USA, Inc.
$514
Merck Sharp & Dohme LLC
$439
Amgen Inc.
$397
Merck Sharp & Dohme Corporation
$377
Lilly USA, LLC
$301
Incyte Corporation
$287
GENZYME CORPORATION
$255
Kite Pharma, Inc.
$235
Eisai Inc.
$229
Seagen Inc.
$215
Daiichi Sankyo Inc.
$210
Ipsen Biopharmaceuticals, Inc
$186
Astellas Pharma US Inc
$180
Exelixis Inc.
$177
NOVARTIS PHARMACEUTICALS CORPORATION
$167
ABBVIE INC.
$152
Bayer Healthcare Pharmaceuticals Inc.
$150
BeiGene USA, Inc.
$143
Bayer HealthCare Pharmaceuticals Inc.
$143
Foundation Medicine, Inc.
$142
Boehringer Ingelheim Pharmaceuticals, Inc.
$137
EMD Serono, Inc.
$134
TESARO, Inc.
$132
Pharmacosmos Therapeutics Inc.
$102
Puma Biotechnology, Inc.
$101
Takeda Pharmaceuticals U.S.A., Inc.
$99
SANOFI-AVENTIS U.S. LLC
$95
TAIHO ONCOLOGY, INC.
$92
JAZZ PHARMACEUTICALS INC.
$90
GlaxoSmithKline, LLC.
$90
Mirati Therapeutics, Inc.
$82
Regeneron Healthcare Solutions, Inc.
$74
ARRAY BIOPHARMA INC
$68
Janssen Pharmaceuticals, Inc
$62
TerSera Therapeutics LLC
$59
Lexicon Pharmaceuticals, Inc.
$58
EISAI INC.
$57
Heron Therapeutics, Inc.
$57
PharmaEssentia USA Corporation
$57
G1 Therapeutics, Inc.
$52
Clovis Oncology, Inc.
$51
AbbVie, Inc.
$48
Alexion Pharmaceuticals, Inc.
$47
AMAG Pharmaceuticals, Inc.
$41
CSL Behring
$39
MEDIVATION FIELD SOLUTIONS LLC
$39
SOBI, INC
$37
Myriad Genetic Laboratories, Inc.
$33
Secura Bio, Inc.
$32
CTI BioPharma Corp.
$30
Stemline Therapeutics Inc.
$29
RECORDATI_RARE_DISEASES_INC.
$29
Alnylam Pharmaceuticals Inc.
$27
Aurobindo Pharma USA, Inc.
$27
Taiho Oncology, Inc.
$26
Aveo Pharmaceuticals, Inc.
$26
Horizon Therapeutics plc
$26
Agios Pharmaceuticals, Inc.
$26
Blueprint Medicines Corporation
$25
Sun Pharmaceutical Industries Inc.
$24
Adaptive Biotechnologies Corporation
$22
Emmaus Medical, Inc.
$18
Global Blood Therapeutics, Inc.
$18
MorphoSys, US Inc.
$18
EUSA Pharma (US) LLC
$17
Coherus Biosciences Inc.
$17
PUMA BIOTECHNOLOGY, INC.
$16
Abbott Laboratories
$16
Pharmacyclics LLC, An AbbVie Company
$16
Jazz Pharmaceuticals Inc.
$15
Dendreon Pharmaceuticals LLC
$14
Array BioPharma Inc.
$13
SECURA BIO, INC.
$11
Teva Pharmaceuticals USA, Inc.
$11
Veracyte, Inc.
$3
Top 3 companies account for 84.7% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Abraxane · Afstyla · Alecensa · Avastin · BAVENCIO · BENDEKA · BESREMI · BOSULIF · BRACANALYSIS CDX · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CINVANTI · COPIKTRA · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELITEK · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · Endari · Enhertu · Erleada · FARYDAK · FASENRA · FERAHEME · FOTIVDA · FOUNDATIONONE · FREESTYLE LIBRE 3 · FRUZAQLA · Fabhalta · Farydak · Folotyn · GAZYVA · GILOTRIF · GIVLAARI · Gazyva · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Idelvion · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · KRYSTEXXA · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MVASI · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · Padcev · Perjeta · Polivy · Pomalyst · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · Rituxan Hycela · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SUSTOL · SUTENT · SYLVANT · Somatuline Depot · Stivarga · Sylvant · TAFINLAR · TAGRISSO · TASIGNA · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Vanflyta · Venclexta · Vitrakvi · Vonjo · Vyloy · XALKORI · XARELTO · XOSPATA · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · YONSA (abiraterone acetate) · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (84%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 3% for hematology in FL.
Equivalent to $171 per 100 Medicare services performed
Geographic Context
Hematologists within 10 mi
9
Per 100K population
1.6
County median income
$66,581
Nearest hospital
ADVENTHEALTH DAYTONA BEACH
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Harris is a mixed practice specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 3% of FL peers, with 17 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Harris experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Harris performed 27,400 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Harris receive payments from pharmaceutical companies?
Yes. Dr. Harris received a total of $150,121 from 85 companies across 879 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Harris's costs compare to other hematologists in Daytona Beach?
Dr. Harris's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Harris) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologists in Daytona Beach
Browse hematologists in Daytona Beach ranked by procedure volume and transparency data.
Highest volume
Top Hematologists in FL
Hematologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologists in FL
Which FL hematologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology